Skip to content

Mustakarishta in the management of Irritable Bowel Syndrome

Clinical evaluation of Mustakarishta in the management of Grahani

Status
Active, not recruiting
Phases
Phase 2Phase 3
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2019/09/021371
Enrollment
100
Registered
2019-09-23
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: K582- Mixed irritable bowel syndrome

Interventions

Intervention1: Mustakarista: Dose : 25 ml twice daily with equal quantity of water Dosage form : Arishta Route of Administration : Oral Time of Administration : Twice a day after food Anupana : W

Sponsors

CCRAS
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Known cases of Grahani (diagnostic criteria as per classical Ayurvedic parameters) Patients willing to give written informed consent to participate in the study

Exclusion criteria

Exclusion criteria: 1. Patients with history of Inflammatory Bowel Disease (IBD), Kochâ??s abdomen, Gluten intolerance. 2. Patients with history of chronic Amoebiasis. 3. Known cases of Diabetes Mellitus. 4. Patients with poorly controlled Hypertension ( >160/100 mmHg) 5. Patients who have history of Atrial Fibrillation, Acute Coronary Syndrome, Myocardial Infarction, Stroke or Severe Arrhythmia in the last 6 months 6. Symptomatic patients with clinical evidence of Heart failure 7. Known cases of malignancy 8. Patients with concurrent serious hepatic disorders (defined as Aspartate Amino Transferase (AST) and / or Alanine Amino Transferase (ALT) > 2 times upper normal limit) or Renal Disorders (defined as S. Creatinine >1.2mg/dL), Severe Pulmonary Dysfunction (uncontrolled Bronchial Asthma and / or Chronic Obstructive Pulmonary Disease (COPD). 9. Women who are planning for conception / pregnant or lactating. 10. H/o hypersensitivity to any of the trial drugs or their ingredients 11. Patients who have completed participation in any other clinical trial during the past three months 12. Any other condition which the Investigator thinks may jeopardize the study

Design outcomes

Primary

MeasureTime frame
To assess the clinical efficacy of Mustakarishta by the assessment of Changes in Ayurvedic Parameters of Grahani.Timepoint: Bseline,on 14th day, 28th day, 42th day, 56th day, 70th day,84th day,98th day

Secondary

MeasureTime frame
To assess the clinical efficacy of Mustakarishta by the assessment of Changes in IBS-QOL score.Timepoint: Baseline,on 14th day, 28th day, 42th day, 56th day, 70th day,84th and 98th day

Countries

India

Contacts

Public ContactDr Gurucharan Bhuyan

Ayurveda Hospital CARIHD, BHUBANESWAR

drbhuyangc@gmail.com06742387702

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026